ExpreS2ion signs Letter of Intent with WuXi Vaccines to initiate technology evaluation of ExpreS2ion’s proprietary production platform ExpreS2™

Hørsholm, Denmark, 15 April 2025 - ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), today announced that ExpreS2ion and WuXi Vaccines have signed a Letter of Intent to initiate a technology evaluation of ExpreS2ion’s proprietary Drosophila S2 expression technology platform (“ExpreS2”) for the bioproduction of vaccines and other biologics. WuXi Vaccines is a World-leading CDMO in the vaccines space, offering its development and manufacturing expertise and equipment to customers worldwide. The Letter of Intent is intended to lead to a strategic